HomeCompareTINT vs MRK

TINT vs MRK: Dividend Comparison 2026

TINT yields 1.16% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.4K in total portfolio value
10 years
TINT
TINT
● Live price
1.16%
Share price
$35.20
Annual div
$0.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$125.32
Full TINT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TINT vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTINTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TINT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TINT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TINT
Annual income on $10K today (after 15% tax)
$98.78/yr
After 10yr DRIP, annual income (after tax)
$106.52/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,221.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TINT + MRK for your $10,000?

TINT: 50%MRK: 50%
100% MRK50/50100% TINT
Portfolio after 10yr
$39.1K
Annual income
$4,961.73/yr
Blended yield
12.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TINT
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TINT buys
0
MRK buys
0
No recent congressional trades found for TINT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTINTMRK
Forward yield1.16%2.76%
Annual dividend / share$0.41$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$21.3K$56.8K
Annual income after 10y$125.32$9,798.13
Total dividends collected$1.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TINT vs MRK ($10,000, DRIP)

YearTINT PortfolioTINT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,816$116.22$11,206$366.19$390.00MRK
2$11,691$117.48$12,650$502.35$959.00MRK
3$12,628$118.67$14,407$694.19$1.8KMRK
4$13,632$119.80$16,585$967.82$3.0KMRK
5$14,707$120.86$19,342$1,363.89$4.6KMRK
6$15,858$121.86$22,913$1,947.19$7.1KMRK
7$17,091$122.80$27,662$2,823.89$10.6KMRK
8$18,411$123.69$34,159$4,173.35$15.7KMRK
9$19,824$124.53$43,337$6,308.80$23.5KMRK
10$21,337$125.32$56,776$9,798.13$35.4KMRK

TINT vs MRK: Complete Analysis 2026

TINTStock

The index selects companies focused on making or applying industrial innovations which allow for improved products, processes, or techniques through advanced, responsive, or intelligent materials. The fund adviser seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction. The fund is non-diversified.

Full TINT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TINT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TINT vs SCHDTINT vs JEPITINT vs OTINT vs KOTINT vs MAINTINT vs JNJTINT vs ABBVTINT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.